Literature DB >> 11036848

Relationship between sex and antibodies to high mobility group proteins 1 and 2 in juvenile idiopathic arthritis.

A M Rosenberg1, D M Cordeiro.   

Abstract

OBJECTIVE: To compare the frequencies of antibodies to high mobility group proteins 1 and 2 (HMG-1, HMG-2) in boys and girls with juvenile idiopathic arthritis (JIA).
METHODS: Sera of 60 children (44 girls, 16 boys) with JIA were screened for the presence of anti-nuclear antibodies (ANA) and antichromatin antibodies by indirect immunofluorescence (IIF) on eukaryotic cells and were assayed further for the presence of antibodies to purified HMG-1 and HMG-2 by enzyme immunoassays.
RESULTS: A positive test for ANA was significantly associated with the presence of antibodies to both HMG-1 and HMG-2. There was a significant association between antibodies targeting the chromosomal regions of metaphase cells and antibodies to both HMG-1 and HMG-2. Females were significantly more likely than males to have ANA, and specifically more likely to have antibodies to HMG-1. There was a significant association between the presence of antibodies to HMG proteins and chromosomal reactivity detected by IIF on HEp-2 cells.
CONCLUSION: The results suggest that females with JIA are more likely to be ANA positive than males and more likely than males to have antibodies to HMG-1.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11036848

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

Review 1.  HMGB proteins and arthritis.

Authors:  Noboru Taniguchi; Yasuhiko Kawakami; Ikuro Maruyama; Martin Lotz
Journal:  Hum Cell       Date:  2017-09-15       Impact factor: 4.174

2.  Native versus recombinant high-mobility group B1 proteins: functional activity in vitro.

Authors:  Klaus Zimmermann; Dirk Völkel; Sabrina Pable; Thomas Lindner; Franziska Kramberger; Soheyl Bahrami; Friedrich Scheiflinger
Journal:  Inflammation       Date:  2004-08       Impact factor: 4.092

Review 3.  High-mobility group box 1 (HMGB1) in childhood: from bench to bedside.

Authors:  Valeria Chirico; Antonio Lacquaniti; Vincenzo Salpietro; Caterina Munafò; Maria Pia Calabrò; Michele Buemi; Teresa Arrigo; Carmelo Salpietro
Journal:  Eur J Pediatr       Date:  2014-05-09       Impact factor: 3.183

Review 4.  High Mobility Group Box 1: a potential therapeutic target for systemic lupus erythematosus.

Authors:  Hai-Feng Pan; Guo-Cui Wu; Wei-Ping Li; Xiang-Pei Li; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2009-02-27       Impact factor: 2.316

5.  B-cell pathology in juvenile idiopathic arthritis.

Authors:  V Wiegering; H J Girschick; H Morbach
Journal:  Arthritis       Date:  2010-12-02

6.  The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus.

Authors:  Dubravka Bobek; Danka Grčević; Nataša Kovačić; Ivan Krešimir Lukić; Marija Jelušić
Journal:  Pediatr Rheumatol Online J       Date:  2014-12-03       Impact factor: 3.054

Review 7.  The role of cell death in the pathogenesis of autoimmune disease: HMGB1 and microparticles as intercellular mediators of inflammation.

Authors:  Stacy P Ardoin; David S Pisetsky
Journal:  Mod Rheumatol       Date:  2008-04-17       Impact factor: 3.023

Review 8.  The spectrum of anti-chromatin/nucleosome autoantibodies: independent and interdependent biomarkers of disease.

Authors:  Sonal Mehra; Marvin J Fritzler
Journal:  J Immunol Res       Date:  2014-04-03       Impact factor: 4.818

9.  Association between high mobility group box 1 protein and juvenile idiopathic arthritis: a prospective longitudinal study.

Authors:  Dan Xu; Yu Zhang; Zhi-Yong Zhang; Xue-Mei Tang
Journal:  Pediatr Rheumatol Online J       Date:  2021-07-12       Impact factor: 3.054

10.  A Master Autoantigen-ome Links Alternative Splicing, Female Predilection, and COVID-19 to Autoimmune Diseases.

Authors:  Julia Y Wang; Michael W Roehrl; Victor B Roehrl; Michael H Roehrl
Journal:  bioRxiv       Date:  2021-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.